Does Dr. SYED ABUTALIB have financial conflicts of interest?

Dr. SYED ABUTALIB (MD) has received a total of $73,793 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $73,793 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. SYED ABUTALIB?

According to CMS Open Payments data, Dr. SYED ABUTALIB received funding from ASTRAZENECA PHARMACEUTICALS ($54,501), ADC THERAPEUTICS AMERICA ($10,228), and EPIZYME ($3,262).

Does Dr. SYED ABUTALIB receive research grants or speaking fees?

Dr. SYED ABUTALIB has received $73,793 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. SYED ABUTALIB

MDReal-Time Hydrated

Specialty: Internal Medicine, Hematology & Oncology

Practice Location: MILWAUKEE, WI 53215

NPI Number: 1114183290

LIFETIME INDUSTRY VALUE

$73,793

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABUTALIB is a verified Internal Medicine, Hematology & Oncology practitioner based in MILWAUKEE, WI.

Between 2021 and 2024, Dr. ABUTALIB had an overall industry promotional and research financial footprint of $73,793 as recorded in the federal CMS Open Payments database.

$73,793 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABUTALIB's primary funding source is ASTRAZENECA PHARMACEUTICALS, which accounts for $54,501 (representing 73.9% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ASTRAZENECA PHARMACEUTICALS

Rank 1

$54,501

73.9%

ADC THERAPEUTICS AMERICA

Rank 2

$10,228

13.9%

EPIZYME

Rank 3

$3,262

4.4%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.